JS Leeder

3.2k total citations · 3 hit papers
10 papers, 2.3k citations indexed

About

JS Leeder is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Oncology. According to data from OpenAlex, JS Leeder has authored 10 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pediatrics, Perinatology and Child Health, 5 papers in Pharmacology and 3 papers in Oncology. Recurrent topics in JS Leeder's work include Pharmacogenetics and Drug Metabolism (5 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Pharmaceutical studies and practices (3 papers). JS Leeder is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Pharmaceutical studies and practices (3 papers). JS Leeder collaborates with scholars based in United States, Canada and United Kingdom. JS Leeder's co-authors include Andrea Gaedigk, R PEARCE, L. DiAnne Bradford, Teri E. Klein, Adrián LLerena, Julia Stingl, J K Hicks, Stuart A. Scott, Yuan Ji and Katrin Sangkuhl and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Pharmacoepidemiology and Drug Safety and Clinical and Translational Science.

In The Last Decade

JS Leeder

10 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

2015 672 citations J K Hicks, Katrin Sangkuhl et al. Clinical Pharmacology & Therapeutics profile →
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

2007 587 citations Andrea Gaedigk, R PEARCE et al. Clinical Pharmacology & Therapeutics profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

2015 499 citations Kelly A. Birdwell, Brian S. Decker et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JS Leeder United States	10	1.3k	904	451	386	317	10	2.3k
JJ Swen Netherlands	8	917 0.7×	593 0.7×	243 0.5×	222 0.6×	344 1.1×	10	1.4k
Christina L. Aquilante United States	26	829 0.6×	468 0.5×	425 0.9×	210 0.5×	93 0.3×	87	2.3k
Henry M. Dunnenberger United States	22	2.2k 1.6×	1.3k 1.4×	412 0.9×	566 1.5×	63 0.2×	47	3.5k
Séverine Crettol Switzerland	18	586 0.4×	454 0.5×	286 0.6×	186 0.5×	136 0.4×	40	1.5k
Jan van der Weide Netherlands	27	1.6k 1.2×	721 0.8×	616 1.4×	415 1.1×	45 0.1×	47	2.8k
Julio Benítez Spain	27	767 0.6×	283 0.3×	399 0.9×	353 0.9×	103 0.3×	52	1.9k
Cyrine E. Haidar United States	19	1.6k 1.2×	948 1.0×	403 0.9×	248 0.6×	35 0.1×	34	2.5k
Caroline Samer Switzerland	28	832 0.6×	440 0.5×	352 0.8×	283 0.7×	45 0.1×	107	2.5k
E D Kharasch United States	14	1.4k 1.0×	569 0.6×	387 0.9×	343 0.9×	29 0.1×	25	2.1k
Sarah C. Sim Sweden	20	1.4k 1.0×	294 0.3×	639 1.4×	330 0.9×	43 0.1×	24	2.1k

Countries citing papers authored by JS Leeder

Since Specialization

Citations

This map shows the geographic impact of JS Leeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JS Leeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JS Leeder more than expected).

Fields of papers citing papers by JS Leeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JS Leeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JS Leeder. The network helps show where JS Leeder may publish in the future.

Co-authorship network of co-authors of JS Leeder

This figure shows the co-authorship network connecting the top 25 collaborators of JS Leeder. A scholar is included among the top collaborators of JS Leeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JS Leeder. JS Leeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Prasad, Bhagwat, Andrea Gaedigk, Marc Vrana, et al.. (2016). Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics. Clinical Pharmacology & Therapeutics. 100(4). 362–370. 113 indexed citations

Islam, Sheikh Mohammed Shariful, et al.. (2016). Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro. Clinical and Translational Science. 9(3). 149–157. 10 indexed citations

Hicks, J K, Katrin Sangkuhl, Müller Dj, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology & Therapeutics. 98(2). 127–134. 672 indexed citations breakdown →

Birdwell, Kelly A., Brian S. Decker, Catherine M. Stein, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology & Therapeutics. 98(1). 19–24. 499 indexed citations breakdown →

Lewis, Tamorah, Jean Dinh, & JS Leeder. (2015). Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clinical Pharmacology & Therapeutics. 98(3). 309–320. 17 indexed citations

Haandel, Leon van, et al.. (2015). Single dose, CYP2D6 genotype‐stratified pharmacokinetic study of atomoxetine in children with ADHD. Clinical Pharmacology & Therapeutics. 99(6). 642–650. 51 indexed citations

Carleton, Bruce, et al.. (2009). Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiology and Drug Safety. 18(8). 713–721. 63 indexed citations

Madadi, P, Colin J.D. Ross, Michael R. Hayden, et al.. (2008). Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study. Clinical Pharmacology & Therapeutics. 85(1). 31–35. 183 indexed citations

Zhang, Yi, L Zhang, Susamma Abraham, et al.. (2008). Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications. Clinical Pharmacology & Therapeutics. 85(3). 305–311. 121 indexed citations

10.

Gaedigk, Andrea, et al.. (2007). The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype. Clinical Pharmacology & Therapeutics. 83(2). 234–242. 587 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact